Substantial improvements in the depth of response prior to transplant has been seen with the use of novel agents such as proteasome inhibitors and immunomodulatory drugs. Depth of response is prognostic for overall outcome after autologous transplant for multiple myeloma. In this review, ongoing trials using these same agents for consolidation and maintenance therapy after transplant are discussed, with some results indicating additional survival benefits. However, the authors note that side effects have been observed with such long-term therapy, and that their use post-transplant remains under debate.
Novel Agents for Consolidation and Maintenance Therapy After Auto-HCT for Multiple Myeloma